New mRNA Flu Vaccine Option for Adults 50+

As flu season approaches, health officials are urging individuals to prepare and get vaccinated. Seasonal flu activity is currently low but typically increases by December and peaks in the winter months.

For the 2026-2027 season, scientists have recommended trivalent flu vaccines targeting Influenza A H1N1, Influenza A H3N2, and Influenza B strains. Experts advise that anyone six months of age or older should receive a flu shot in the fall, ideally between September and October. This timing allows the immune system two weeks to develop protective antibodies before the peak season.

A new option this year is Moderna's mRNA flu vaccine, mFLUSIVA, approved by the FDA for adults aged 50 and older. This vaccine works by instructing cells to train the immune system. Reported side effects are generally mild, similar to other vaccines, and may include fatigue or injection site pain.

While most people should get vaccinated, certain individuals are advised against it. This includes children under six months old and anyone with a severe, life-threatening allergy to vaccine ingredients like gelatin or antibiotics, or a history of severe allergic reactions to flu vaccines. Consulting a doctor is recommended for personalized advice.